Galapagos NV (LTS:0JXZ)
€ 26.19 0 (0%) Market Cap: 1.73 Bil Enterprise Value: -1.60 Bil PE Ratio: 8.38 PB Ratio: 0.60 GF Score: 51/100

Galapagos NV at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 12:30AM GMT
Release Date Price: €43.05 (+2.79%)
James Daniel Gordon
JPMorgan Chase & Co, Research Division - Senior Analyst

Good afternoon. I'm James Gordon, J.P. Morgan European Pharma and Biotech Analyst. And today, I've got the pleasure of introducing the Galapagos presentation. So, you're going to hear from Galapagos CEO, Paul Stoffels and we're going to have a 20-minute Q&A in this room after the presentation.

So with that said, thanks a lot for joining us today, Paul. Looking forward to the presentation.

Paulus A. Stoffels
Galapagos NV - CEO, Chairman, Head of R&D & Member of Management Board

Good afternoon. My name is Paul Stoffels. As said, I'm the CEO of Galapagos. After retiring from J&J, where I worked for 30 years as mainly in the science, but as Chief Scientific Officer for the last 10 years, returned back to Europe and took the reins of a company, which I co-founded back in '98. And so it was going back home for me, recharging Galapagos for the future. And so, I'll give you a short summary of the story, what we are doing at the moment and the new products, new

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot